18 results found.

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma.
veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Systemic Anaplastic Large-Cell Lymphoma, Neoplasms, Anaplastic Ly Clinical Trial using PF-02341066; Rifampin; Ketoconazole

Pfizer - Recruiting 18 years or older.
- Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer.
PF-02341066; Rifampin; Ketoconazole

Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Clinical Trial using plerixafor; filgrastim; etoposide; leukapheresis

Case Comprehensive Cancer Center - Recruiting 18 years to 78 years.
- A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma.
plerixafor; filgrastim; etoposide; leukapheresis

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Anaplastic Large-cell Lymphoma Clinical Trial using brentuximab vedotin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
brentuximab vedotin

Stage II Childhood Anaplastic Large Cell Lymphoma, Stage III Chil Clinical Trial using brentuximab vedotin; crizotinib; dexamethasone; ifosfamide; methotrexate; cytarabine; etoposide; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) IND # 117117.
brentuximab vedotin; crizotinib; dexamethasone; ifosfamide; methotrexate; cytarabine; etoposide; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lympho Clinical Trial using SGN-35

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP).
SGN-35

Hodgkin Lymphoma, or Anaplastic Large Cell Lymphoma Clinical Trial using Adcetris; Bendamustine

Columbia University - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma.
Adcetris; Bendamustine

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Morphotek - Recruiting 13 Months to 21 years.
- Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors.
anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using alisertib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma.
alisertib; pharmacological study; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using carfilzomib; laboratory biomarker analysis

University of Nebraska - Recruiting 19 years or older.
- Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma.
carfilzomib; laboratory biomarker analysis

Advanced Malignancies, Carcinoma, Non-Small-Cell Lung, Anaplastic Clinical Trial using AP26113

Ariad Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113.
AP26113

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study